Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Dec;99(12):2831-2836.
doi: 10.1007/s00277-020-04284-z. Epub 2020 Sep 28.

Long-term follow-up of abbreviated R-CHOP chemoimmunotherapy for completely resected limited-stage diffuse large B cell lymphoma (CISL 12-09)

Sora Kang  1 , Hyungwoo Cho  2 , Byeong Seok Sohn  3 , Sung Yong Oh  4 , Won-Sik Lee  5 , Sang Min Lee  5 , Deok-Hwan Yang  6 , Jooryung Huh  7 , Dok Hyun Yoon  8 , Cheolwon Suh  9
Affiliations

Long-term follow-up of abbreviated R-CHOP chemoimmunotherapy for completely resected limited-stage diffuse large B cell lymphoma (CISL 12-09)

Sora Kang et al. Ann Hematol. 2020 Dec.

Abstract

The standard of treatment for completely resected limited-stage diffuse large B cell lymphoma (DLBCL) in patients without residual lesions has not yet been established. Previously, we designed a phase II trial to evaluate the safety and efficacy of three cycles of abbreviated R-CHOP in patients with completely resected limited-stage DLBCL and reported favorable survival outcomes. We present the long-term follow-up results to taking into account the importance of delayed relapse in patients with limited-stage DLBCL. With a median follow-up duration of 62.7 months (range, 60.2-75.5 months), the 5-year OS and DFS rates were both 95.0% (95% confidence interval, 85.59-104.11%). Only one patient experienced disease progression which was confirmed at 12.3 months, and one patient with primary intestinal DLBCL developed non-small cell lung cancer 6 years after treatment. The long-term results of our data support the use of three cycles of abbreviated R-CHOP for patients with completely resected limited-stage DLBCL. The study was reviewed and approved by the review boards of the participating institutes and registered at ClinicalTrials.gov , number NCT01279902, in August 3, 2010.

Keywords: Complete resection; Diffuse large B cell lymphoma; Limited stage; R-CHOP.

PubMed Disclaimer

References

    1. Pfreundschuh M, Kuhnt E, Trümper L, Österborg A, Trneny M, Shepherd L, Gill DS, Walewski J, Pettengell R, Jaeger U, Zinzani P-L, Shpilberg O, Kvaloy S, Brown PN, Stahel R, Milpied N, López-Guillermo A, Poeschel V, Grass S, Loeffler M, Murawski N, Group ftMIT (2011) CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol 12(11):1013–1022. https://doi.org/10.1016/s1470-2045(11)70235-2 - DOI - PubMed
    1. Lamy T, Damaj G, Soubeyran P, Gyan E, Cartron G, Bouabdallah K, Gressin R, Cornillon J, Banos A, Du KL, Benchalal M, Moles M-P, Gouill SL, Fleury J, Godmer P, Maisonneuve H, Deconinck E, Houot R, Laribi K, Marolleau JP, Tournilhac O, Branger B, Devillers A, Vuillez JP, Fest T, Colombat P, Costes V, Szablewski V, Béné MC, Delwail V (2018) R-CHOP 14 with or without radiotherapy in nonbulky limited-stage diffuse large B-cell lymphoma. Blood 131(2):174–181. https://doi.org/10.1182/blood-2017-07-793984 - DOI - PubMed - PMC
    1. Persky DO, Unger JM, Spier CM, Stea B, LeBlanc M, McCarty MJ, Rimsza LM, Fisher RI, Miller TP (2008) Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group Study 0014. J Clin Oncol 26(14):2258–2263. https://doi.org/10.1200/jco.2007.13.6929 - DOI - PubMed
    1. Sehn LH (2012) Chemotherapy alone for localized diffuse large B-cell lymphoma. Cancer J 18(5):421–426. https://doi.org/10.1097/ppo.0b013e31826c5907 - DOI - PubMed
    1. Sehn LH, Savage KJ, Hoskins P, Klasa R, Shenkier T, Voss N, Wilson D, Connors JM (2007) Limited-stage diffuse large B-cell lymphoma (DLBCL) patients with a negative pet scan following three cycles of R-CHOP can be effectively treated with abbreviated chemoimmunotherapy alone. Blood 110(11):787–787. https://doi.org/10.1182/blood.v110.11.787.787 - DOI

MeSH terms

Associated data

LinkOut - more resources